OncBioMune Pharmaceuticals, Inc. (OBMP) financial statements (2021 and earlier)

Company profile

Business Address 11441 INDUSTRIPLEX BLVD
BATON ROUGE, LA 70809
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21136  0502
Cash and cash equivalents21136  0502
Other undisclosed current assets4123519020421622617
Total current assets:6237119020421627720
Noncurrent Assets
Operating lease, right-of-use asset24334150
Property, plant and equipment2334455
Intangible assets, net (including goodwill)     (4,737) 
Goodwill     (4,737) 
Other undisclosed noncurrent assets666664,7436
Total noncurrent assets:32425160111112
TOTAL ASSETS:9441324126422728832
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,1752,2441,9121,7361,4341,135911
Accounts payable620858740713550458381
Accrued liabilities1,5541,3861,1721,023884677530
Debt3,4783,3353,2242,6121,9731,3331,468
Derivative instruments and hedges, liabilities9,3207,4776,9346,3563,3647,0426,430
Due to related parties373347347347315334339
Disposal group, including discontinued operation687687687687687687687
Total current liabilities:16,03214,09013,10411,7387,77410,5319,835
Noncurrent Liabilities
Long-term debt and lease obligation  615   
Operating lease, liability  615
Total noncurrent liabilities:  615   
Total liabilities:16,03214,09013,11011,7537,77410,5319,835
Stockholders' equity
Stockholders' equity attributable to parent, including:(15,937)(13,677)(12,869)(11,488)(7,547)(10,243)(9,803)
Common stock003229252523
Additional paid in capital10,65210,55910,34510,1179,6139,4239,220
Accumulated deficit(26,590)(24,236)(23,248)(21,636)(17,188)(19,692)(19,047)
Other undisclosed stockholders' equity attributable to parent0022311
Total stockholders' equity:(15,937)(13,677)(12,869)(11,488)(7,547)(10,243)(9,803)
TOTAL LIABILITIES AND EQUITY:9441324126422728832

Income statement (P&L) ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Operating expenses(281)(410)(515)(563)(495)(493)(344)
Operating loss:(281)(410)(515)(563)(495)(493)(344)
Nonoperating income (expense)(2,073)(578)(1,097)(3,886)2,999(151)(4,365)
Interest and debt expense(1)(0)(39)(37)3,506(650)(339)
Income (loss) from continuing operations before income taxes:(2,355)(988)(1,651)(4,485)6,010(1,295)(5,048)
Other undisclosed income (loss) from continuing operations103937(3,506)650339
Net income (loss) available to common stockholders, basic:(2,354)(988)(1,612)(4,449)2,504(645)(4,709)
Other undisclosed net loss available to common stockholders, diluted    (1,391)  
Net income (loss) available to common stockholders, diluted:(2,354)(988)(1,612)(4,449)1,113(645)(4,709)

Comprehensive Income ($ in thousands)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net income (loss):(2,354)(988)(1,612)(4,449)2,504(645)(4,709)
Other comprehensive income (loss)  (1,612)(4,449)2,504(645)(4,679)
Comprehensive income (loss), net of tax, attributable to parent:(2,354)(988)(3,224)(8,897)5,008(1,289)(9,388)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: